Zimmer Biomet Raises €500M Despite Earnings Beat Streak
Zimmer Biomet has beaten analyst EPS estimates in four consecutive quarters with a trailing free cash flow of $1.44 billion and a 69.3% gross margin, yet the company issued €500 million in new notes o
Zimmer Biomet Issues €500M Notes Amid Four Straight Beats
NEW YORK, November 13 —
Zimmer Biomet Holdings, Inc. (ZBH) has beaten analyst EPS estimates in four straight quarters, yet the orthopedic implant maker just added €500 million in new notes to a balance sheet carrying $7.66 billion in debt against $0.43 billion cash. Three senior executives sold a combined $820,000 in shares at prices the stock has since climbed past.
- €500M in new notes closed November 12; total debt $7.66B against $0.43B cash, net debt roughly $7.23B.
- Net insider activity over 90 days: $820,000 in sales across three executives; zero open-market purchases.
The Robotics Franchise Earning Its Discount
Zimmer Biomet designs and sells knee and hip replacement implants to hospitals and orthopedic surgeons, with roughly 17,000 employees worldwide. Its ROSA Robot assists surgeons with implant positioning in total and partial knee arthroplasty, while the ZBEdge Platform layers data analytics and AI over pre-, intra-, and post-surgical workflows. That combination has produced four consecutive EPS beats, the largest of which hit 12.3% in Q1 2026, alongside $1.44 billion in trailing free cash flow and a 69.3% gross margin. A forward P/E of 11.5x on that earnings record is undemanding for a large-cap medical device franchise with a maturing robotics platform.
€500 Million of Confidence, or Complacency
The November 12 8-K disclosed a new debt transaction; market reports put the total at €500 million, with interest deferred until November 2027. The notes land on a balance sheet carrying $7.23 billion in net debt at a company growing revenue at 3.1%. The bull case is that the notes fund the ROSA and ZBEdge digital-surgery expansion; the DCF calculator can frame what a revenue stall would do to fair value.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ZBH | $19.6B | 11.5x | +16.3% |
| IQV | $43.5B | 18.6x | +22.9% |
| TFX | $6.1B | 14.1x | +43.1% |
| COO | $11.9B | 13.4x | -13.8% |
| EW | $61.6B | 31.6x | +22.6% |
| FTV | $20.2B | 20.4x | +31.5% |
Every Insider Exit Below Today's Price
The insider selling complicates the bull case without invalidating it. Kevin R. Thornal sold 5,691 shares at $92.95 on September 11; Chad F. Phipps sold 3,000 at $98.35 on September 4; Gary Craig Campbell sold 1,412 at $88.42 on October 1. All three exited below $103.50, while insiders who collectively own 0.1% of shares made zero open-market purchases across the period. The position is neutral: 11.5x forward P/E and durable FCF are real, but the thesis breaks if ZBH cannot push revenue growth past 3.1% as robotics adoption matures. Run the free Zimmer Biomet Holdings, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Has Zimmer Biomet beaten earnings estimates?
Yes, Zimmer Biomet has beaten analyst EPS estimates in four consecutive quarters. Q3's actual earnings came in at $1.90 versus a $1.881 estimate, and Q1 2026 saw the largest outperformance at 12.3%.
Why did Zimmer Biomet issue debt?
On November 12, Zimmer Biomet issued €500 million in new notes with interest deferred until November 2027. The bull case is that the notes fund the ROSA Robot and ZBEdge digital-surgery platform expansion.
Are Zimmer Biomet executives selling stock?
Yes, three senior executives sold a combined $820,000 in shares over 90 days, all at prices below the current stock price above $103.50. Kevin R. Thornal sold 5,691 shares at $92.95 on September 11, Chad F. Phipps sold 3,000 at $98.35 on September 4, and Gary Craig Campbell sold 1,412 at $88.42 on October 1.
What is Zimmer Biomet's valuation?
Zimmer Biomet trades at a forward P/E of 11.5x on its strong earnings record. This is considered undemanding for a large-cap medical device franchise, though operating cash flow of $1.885 billion provides limited headroom against $7.23 billion in net debt.
What does Zimmer Biomet manufacture?
Zimmer Biomet designs and sells knee and hip replacement implants serving hospitals and orthopedic surgeons worldwide. Its ROSA Robot assists surgeons with implant positioning in total and partial knee arthroplasty, while the ZBEdge Platform layers data analytics and AI over surgical workflows.
Zimmer Biomet has beaten analyst EPS estimates for four straight quarters, yet the orthopedic device maker just raised €500 million in new notes on top of $7.66 billion in existing debt — while two senior executives sold a combined $824,000 in shares at prices the stock has since climbed past.